Drug cessation in complex older adults: Time for action by Cammen, T.J.M. (Tischa) van der et al.
REVIEW
Drug cessation in complex older adults:
time for action
TISCHA JM VAN DER CAMMEN1,2,3, CHAKRAVARTHI RAJKUMAR4, GRAZIANO ONDER5,
CAROLYN S STERKE6,7, MIRKO PETROVIC8
1Internal Medicine – Section of Geriatric Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
2Department of Medicine, Brighton and Sussex Medical School, Brighton, UK
3Faculty of Industrial Design Engineering, Delft University of Technology, Delft, Netherlands
4Brighton & Sussex Medical School – Elderly Care, Audrey Emerton Building Royal Sussex County Hospital, Brighton BN2 5BE, UK
5Department of Geriatrics, Policlinico A. Gemelli Catholic University of the Sacred Heart, Rome, Italy
6Aafje thuiszorg huizen zorghotels, Rotterdam, Netherlands
7Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands
8Department of Geriatrics and Gerontology, Ghent University Hospital, Ghent, Belgium
Address correspondence to: Tischa Jm van der Cammen. Email: t.vandercammen@erasmusmc.nl
Abstract
Background: general opinion is growing that drug cessation in complex older patients is warranted in certain situations. From
a clinical viewpoint, drug cessation seems most warranted in four situations, i.e., falls, delirium, cognitive impairment and end-
of-life situations. To date, little information about the effects of drug cessation in these four situations is available.
Objectives: to identify the effects and effectiveness of drug cessation on falls, delirium and cognitive impairment. For end-of-
life situations, we reviewed cessation of inappropriate drug use.
Methods: electronic databases were searched using MeSH terms and relevant keywords. Studies published in English were
included if they evaluated the effects of drug cessation in older persons, aged ≥65 years, with falls, delirium or cognitive impair-
ment; or cessation of inappropriate drug use in end-of-life situations.
Results: we selected seven articles for falls, none for delirium, two for cognition and two for end-of-life situations. Withdrawal
of psychotropics reduced fall rate; a prescribing modification programme for primary care physicians reduced fall risk.
Withdrawal of psychotropics and a systematic reduction of polypharmacy resulted in an improvement of cognition. Very little
rigorous research has been conducted on reducing inappropriate medications in patients approaching end of life.
Conclusion: little research has focussed on drug cessation. Available studies showed a beneficial impact of cessation of psy-
chotropic drugs on falls and cognitive status. More research in this field is needed. The issue of systematic drug withdrawal in
end-of-life cases is controversial, but is increasingly relevant in the face of rising numbers of older people of this clinical status.
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Introduction
Older patients are particularly prone to adverse drug reac-
tions (ADR) because age is associated with changes in
pharmacokinetics and pharmacodynamics that may alter
drug metabolism. Multimorbidity and polypharmacy are
common, but protocols for stopping medication in these
circumstances are scarce.
In an evaluation of the applicability of clinical practice
guidelines (CPGs) to the care of older individuals with
several comorbid diseases, Boyd et al. [1] indicate that in the
complex patient with multimorbidity, interactions can also
occur from adherence, such as interactions between a medi-
cation and a disease other than the target disease; medi-
cations for different diseases; medications and food.
Consequently, adhering to current CPGs in caring for an
older person with several comorbidities may have undesir-
able effects [1].
While the impact of drug use on health outcomes in older
patients is quite well known, the impact of drug use on func-
tional outcomes, such as falls, delirium and cognitive impair-
ment, is less well known.
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General opinion is growing that cessation of drugs in
complex older patients should be considered in certain situa-
tions, where cessation rather than prescribing might be bene-
ficial.
We believe that, from a clinical point of view, the principle of
drug cessation is most warranted in four situations, i.e. in older
adults presenting with falls, delirium or cognitive impairment
and in end-of-life situations. To date, information about the
effects of drug cessation in these four situations is scarce.
Therefore, we conducted a literature review on the effects
of drug cessation on falls, delirium and cognitive impair-
ment. In addition, we reviewed the literature for articles on
drug cessation at the end of life.
Methods
We identified falls, delirium, cognitive impairment and
end-of-life situations as high-risk situations for ADR in
complex older adults.
Electronic databases (Medline, EMBASE, Cochrane
Library, CINAHL, PsychLit) were searched for meta-analyses,
reviews and recent large RCTs, using MeSH terms and rele-
vant keywords. Studies published in English between 1
January 2008 and 1 May 2013 were included if they evaluated
the effects of cessation of drug use in older adults, aged ≥65
years, with falls, delirium or cognitive impairment and
studies that reviewed cessation of inappropriate drug use in
end-of-life situations.
As keywords we used ‘drug cessation’, ‘medication
cessation’, ‘drug withdrawal’, ‘medication withdrawal’, ‘drug
discontinuation’, ‘medication discontinuation’, ‘polyphar-
macy reduction’, ‘falls’, ‘delirium’, ‘cognitive impairment’ and
‘end-of-life’.
For end of life, we also searched for ‘inappropriate drug
use’ or ‘inappropriate medication’ and ‘end-of-life’. Two
authors conducted the review process (TISCHA JM VAN
DER CAMMEN and CAROLYN S STERKE).
Subjects at risk (1): older fallers
Falls among the older population are associated with a high
morbidity and mortality. Approximately 30% of community-
dwelling persons ≥65 years fall at least once a year. About
half of these fallers (15%) fall more than once a year. Falls
are more common in nursing home residents, with an inci-
dence approaching 50%. The incidence of falls is age-related
and increases with age, with the highest incidence in the
oldest old.
Falls in older persons are usually of multifactorial origin.
In the complex situation of multimorbidity and polyphar-
macy, which in older persons is often ‘the rule rather than
the exception’, drug use may present an additive risk or con-
tributing factor to falls (=‘excess risk’), i.e. in cases of pre-
existent poor homeostasis (i.e., psychotropic drugs further
impairing balance in patients with a previous stroke or poly-
neuropathy).
In the past decade, drugs that increase fall risk have been
identified, initially in the meta-analysis by Leipzig et al. [2, 3],
followed by a new meta-analysis by Woolcott et al. [4]. The
drug classes predominantly associated with falls in older
adults were the psychotropics, defined as antipsychotics, ben-
zodiazepines (anxiolytics, hypnotics and sedatives) and anti-
depressants [2–4].
On the topic of polypharmacy and fall risk we found one
article describing the association between total drug burden
and falls in residential aged care facilities [5].
The authors used the Drug Burden Index (DBI), a
measure of a person’s total exposure to anticholinergic and
sedative medications that includes principles of dose–
response and maximal effect and is associated with impaired
physical function in community-dwelling older people, and
evaluated the association between the DBI and falls in resi-
dents of residential aged care facilities. They found a signifi-
cant and independent association between the DBI and falls
in older people living in residential aged care facilities and
recommend interventional studies, to determine whether re-
ducing DBI, through dose reduction or cessation of anti-
cholinergic and sedative drugs can prevent falls [5].
Evidence for the effects of drug cessation on falls
We found 48 reviews and 210 RCTs. We selected five reviews
[6–10] and two specific articles [11, 12] included in the
reviews, which demonstrated the effectiveness of drug cessa-
tion on falls in older adults [11, 12] (Box 1 and 2).
In the Cochrane Database Syst Rev 2009 [6], in the
WITHDRAWN review [7] and in the most recent update of
the Cochrane Database Syst Rev 2009 [8], the current body
of knowledge is summarised. Medication review and modifi-
cation were not effective in reducing rate of falls or risk of
falling [8]. Risk of falling was expressed by the risk ratio,
Box 1. Summary on the effectiveness of
drug cessation on falls
Withdrawal of psychotropics is effective in reducing rate
of falls [6–11].
A prescribing modification programme for primary care
physicians significantly reduced risk of falling [8, 12].
Box 2. Summary on the effectiveness of
drug cessation on delirium and cognitive
impairment
No studies available on drug cessation in delirium.
Withdrawal of psychotropics is associated with improved
cognition [10].
Systematic reduction of polypharmacy in community-
dwelling older adults can result in an improvement of
cognitive function [18].
21
Drug cessation in older adults







which compares the number of people who fall once or
more; rate of falling was expressed by falls per person year
[8]. Gradual, stepwise withdrawal of psychotropic medication
in a placebo-controlled trial (CT) significantly reduced rate of
falls, but not risk of falling [6–8, 11]. A prescribing modifica-
tion programme for primary care physicians significantly
reduced risk of falling [8, 12]. This programme included a
major educational component for family physicians, with a
face-to-face education by a clinical pharmacist and feedback
on prescribing practices, as well as financial rewards. This,
combined with self-assessment of medication use by their
patients and subsequent medication review and modification,
resulted in a significantly reduced risk of falling [8, 12].
A review [9] of the literature specifically relating to the
effect of psychotropic medications on falls in older people,
and with a particular focus on evidence supporting minimisa-
tion of their use to reduce risk of falls, confirmed the evidence
[11] that gradual, stepwise withdrawal of psychotropic medica-
tion reduced rate of falls, but not risk of falling [9, 11].
In a systematic review [10] of the benefits and risks of
medication withdrawal in older people as documented in
published trials of medication withdrawal of specific classes
of medications in patient populations with a mean age of
≥65 years, withdrawal of psychotropics was associated with a
reduction in falls [10].
Summary on the effectiveness of drugs cessation in
falls
Withdrawal of psychotropics is effective in reducing rate of
falls [6–11].
A prescribing modification programme for primary care
physicians significantly reduced risk of falling [8, 12].
Subjects at risk (2): older persons with
delirium or cognitive impairment
The risk of drug-induced delirium is high in frail older
people, and in those with dementia. In addition to polyphar-
macy, altered pharmacokinetics and pharmacodynamics and
associated co-morbidities have an additive or synergistic role
with drugs in causing delirium.
Medications are considered responsible for up to 39% of
delirium cases in older people [13].
Many drugs have been associated with delirium, but certain
classes of drugs are more commonly viewed as causative
agents for delirium, including psychotropics, anticonvulsants,
antiparkinson agents, opioid analgesics, gastrointestinal agents,
i.e. antispasmodics, cimetidine, cardiovascular medications, i.e.
antiarrhythmics, digoxin, antihypertensives (β-blockers, methyl-
dopa), steroids [14].
The anticholinergic properties of these drugs probably
play a causative role [14].
Rudolph et al. [15] developed the Anticholinergic Risk
Scale (ARS), a ranked categorical list of commonly pre-
scribed medications with anticholinergic potential. Higher
ARS scores were associated with significantly increased risk
of anticholinergic adverse effects in older patients [15].
The authors recommend the ARS as a tool for identifying
patients at risk of anticholinergic toxic reactions and as an
educational aid for clinicians to identify medications with
anticholinergic adverse effects so that they might avoid
prescription [15].
For polypharmacy and delirium, Inouye and Charpentier
[16] identified the addition of more than three medications
during hospitalisation (RR, 2.9; 95% CI, 1.6–5.4) as one of
five independent precipitating factors for delirium in older
hospitalised patients [16].
For drug-induced cognitive impairment, we found one
review article [17] reporting that non-amnestic mild cognitive
deficits are consistently induced by first-generation antihista-
mines and tricyclic antidepressants, while BZD provoke
combined amnestic and non-amnestic impairments [17]. The
authors recommend that risk-benefit considerations are dis-
cussed with patients in order to enable an informed choice
about drug discontinuation or substitution to potentially
reverse cognitive adverse effects [17].
Evidence for the effects of drug cessation on
delirium and cognitive impairment
We found 26 reviews and 59 RCTs addressing drug-induced
delirium. We found no articles on the effects of drug cessa-
tion in delirium, which is understandable, given its multifac-
torial origin and complexity.
We found one review article [13] with specific recommen-
dations for a medication review in older patients presenting
with delirium, advising a thorough medication history, in order
to determine if any new medications have been initiated, if
medications have been discontinued, and the details of any
recent dosage adjustments that have taken place [13].
When using cognitive impairment as a keyword, we
found one systematic review [10] of published trials of medi-
cation withdrawal demonstrating that withdrawal of psycho-
tropics was associated with improved cognition, and one
prospective cohort study [18] on systematic reduction of
polypharmacy demonstrating that reduction of polyphar-
macy led to improved cognition in 56 out of 64 patients.
In this prospective cohort study [18], an algorithm was
applied for a trial of discontinuation of all drug therapies not
immediately essential for life. The study included consecutive
older community-dwelling patients referred by their family
physician or family for comprehensive geriatric assessment in
a Geriatric-Palliative Department. Drug cessation was
recommended in 64 patients. In three out of 64 patients
(ages 84, 85 and 73 years) a substantial improvement of cog-
nitive impairment was observed (increases in absolute
Mini-Mental State Examination score from 14 to 24, from
14 to 23 and from 14 to 30 points at 6–8 weeks after discon-
tinuation of 7, 7 and 6 drugs, respectively). In total, in 56
(out of 64) patients improvements of cognitive impairment
were reported; all occurred in the first couple of months fol-
lowing drug cessation and were maintained throughout
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follow-up assessments (mean follow-up 19.2 months,
SD ± 11.4 months) [18].
However, the existing evidence for restoration of previous
level of cognitive functioning after drug cessation is scarce,
and articles or patient series on drug cessation as an interven-
tion for cognitive impairment, dementia or drug-induced
delirium are lacking in the literature.
Summary on the effectiveness of drug cessation in
delirium and cognitive function
No articles were available on the effects of drug cessation on
delirium.
Withdrawal of psychotropics is associated with improved
cognition [10].
Systematic reduction of polypharmacy can result in an
improvement of cognitive function [18].
Drug cessation at the end of life
In medicine, nursing and the allied health professions,
end-of-life care refers to health care, not only of patients in
the final hours or days of their lives, but more broadly care of
all those with a terminal illness or terminal condition that has
become advanced, progressive and incurable. End-of-life
care requires a range of decisions, including questions of
palliative care, patients’ right to self-determination, medical
experimentation, the ethics and efficacy of extraordinary or
hazardous medical interventions and the ethics and efficacy
even of continued routine medical interventions [19].
Among older adults with limited life expectancy, clinical
benefits derived from use of multiple drugs and in particular
those aimed at prolonging life or preventing clinical events,
are negligible and do not counterbalance the risk of iatrogen-
ic illness. Discontinuation of drugs in end-of-life care is not
standard practice and clear guidelines on drug use to treat
chronic and acute diseases at the end of life are not available
so far. Avoiding or discontinuing drugs aimed at prolonging
life or preventing clinical events may seem reasonable when
the time needed to obtain the expected benefits from the
drugs is longer than the estimated life expectancy of a par-
ticular individual, and when they do not offer symptomatic
benefits [20]. O’Mahony recently suggested the conversion
of major polypharmacy to ‘oligopharmacy’ (i.e. ≤5 daily
drugs), to avoid the onset of serious adverse drug events in
patients with limited life expectancy [21].
For recommendations on medication review in end-of-
life care, we found one review article [22] and one CT [23]. In
the review article [22], the authors provide an ethically sound,
evidence based discussion of the benefits and harms of medi-
cations commonly used in primary care among older patients.
They point out that in frail older patients, who often have
multimorbidity and functional impairments, symptom control,
maintaining function and addressing end-of-life issues become
the main priorities. ‘Thinking through the medication list’
should be applied in patients at the end of life [22].
In the CT [23] on end-of-life care, the circumstances
related to end-stage care of non-cancer nonagenarians (with
end-stage congestive heart failure or dementia) in an acute
care hospital were compared with those from a sample of
younger patients; a prospective assessment was carried out
of the written instructions for the following actions: do not
resuscitate orders, the graduation of therapeutic decisions, in-
formation provided to relatives about prognosis, total with-
drawal of normal drug therapy and provision of palliative
care. Drug therapy was withdrawn in 66% of cases and ter-
minal palliative care was initiated in 69%. The authors con-
clude that there is room for improvement in end-of-life care
for the oldest-old patients with end-stage non-cancer chronic
diseases [23].
For cessation of inappropriate medication and end of
life, we found six reviews, two fulfilled the selection criteria
[24, 25], one systematic review [24] and one narrative review [25].
In the systematic review [24] of the literature for overuse
of inappropriate medications in frail older adults with limited
life expectancy, 21 studies were identified that used implicit
criteria to identify inappropriate medications (including
drugs without indication, unnecessary duplication and lack
of effectiveness) [24]. Overall intervention effect sizes could
not be determined due to heterogeneity of study designs,
samples and measures. The authors conclude that very little
rigorous research has been conducted on reducing inappro-
priate medications in frail older adults or patients approach-
ing the end of life [24].
The narrative review [25] addressed medication use in
persons with limited life expectancy; the authors found that a
considerable proportion of individuals with a known termin-
al condition continued to take chronic disease preventive
medications until death, despite questionable benefit. As
death approached, there was an indication that a shift from a
curative to palliative goal of care translated into a shift in
medication use. The authors conclude that there is a need to
develop consensus criteria to assess appropriate versus in-
appropriate medication use, specifically for individuals at the
end of life [25].
Summary for medication use in end-of-life situations
Very little rigorous research has been conducted on reducing
inappropriate medications in frail older adults or patients
approaching end of life [24].
Box 3. Summary for medication use in
end-of-life situations
Very little rigorous research has been conducted on redu-
cing inappropriate medications in frail older adults or
patients approaching end of life [24].
There is a need to develop consensus criteria to assess ap-
propriate versus inappropriate medication use, specifically
for individuals at the end of life [25].
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There is a need to develop consensus criteria to assess ap-
propriate versus inappropriate medication use, specifically
for individuals at the end of life [25] (Box 3).
Conclusions
Medical complexity of older adults may have a great role in
the onset of ADR and should always be considered before
prescribing a pharmacological treatment in older patients [26].
Drug cessation in complex older patients is warranted in
certain situations, where cessation rather than prescribing
might be beneficial.
We reviewed the literature for effects of drug cessation on
falls, delirium and cognitive impairment, and for cessation of
inappropriate medication in end-of-life situations. There is
evidence that withdrawal of psychotropics is effective in re-
ducing rate of falls [6–11], and that a prescribing modifica-
tion programme for primary care physicians can reduce risk
of falling [8, 12].
Withdrawal studies in delirium are lacking. Withdrawal of
psychotropics was associated with improved cognition [10]; a
systematic reduction of polypharmacy in community-dwelling
older adults resulted in an improvement of cognitive function
in a considerable number of patients [18].
For end-of-life situations, very little rigorous research has
been conducted on reducing inappropriate medications in
frail older adults or patients approaching end of life [24];
there is a need to develop consensus criteria to assess appro-
priate versus inappropriate medication use [25]; the conver-
sion of major polypharmacy to ‘oligopharmacy’ in patients
with limited life expectancy deserves attention [21].
At the end of life, careful assessment of medication is
necessary, in order to avoid inappropriate treatments and




• Effects of drug cessation on falls.
• Effects of drug cessation on delirium.
• Effects of drug cessation on cognitive impairment.
• Cessation of inappropriate medication in end-of-life
situations.
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